Valneva Announces Positive Phase 2 Results for Chikungunya Vaccine in Children

Valneva ( (VALN) ) just unveiled an update.

On June 5, 2025, Valneva SE announced positive six-month antibody persistence and safety data from its Phase 2 trial of the chikungunya vaccine IXCHIQ® in children aged one to eleven. The trial showed that the full dose of the vaccine elicited a more robust immune response compared to the half dose, confirming its selection for the upcoming Phase 3 trial. The vaccine was well tolerated, with no safety concerns, and demonstrated a 96.5% seroresponse rate in CHIKV-naïve children. This development is significant given the high incidence of chikungunya in regions like Brazil and India, and the potential for the vaccine to offer long-term protection, especially in low- and middle-income countries where access to vaccines is limited.

The most recent analyst rating on (VALN) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.

Spark’s Take on VALN Stock

According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.

Valneva’s overall score is primarily influenced by its challenging financial performance and valuation concerns, with weak technical analysis further weighing down the score. Positive factors include strong revenue growth and regulatory achievements highlighted in the earnings call.

To see Spark’s full report on VALN stock, click here.

More about Valneva

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company focuses on providing first-, best-, or only-in-class vaccine solutions and currently markets three proprietary travel vaccines, including the world’s first and only chikungunya vaccine. Valneva has a strong track record of advancing vaccines from early R&D to approvals and collaborates with partners like Pfizer on vaccine candidates, such as the only Lyme disease vaccine candidate in advanced clinical development.

Average Trading Volume: 77,359

Technical Sentiment Signal: Sell

Current Market Cap: $537.4M

See more data about VALN stock on TipRanks’ Stock Analysis page.